AC Immune (NASDAQ:ACIU) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Geri Gentry on Oct 8th, 2026

AC Immune (NASDAQ:ACIU – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.50.

A number of research firms recently weighed in on ACIU. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research note on Wednesday, September 23rd. Weiss Ratings upgraded shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Zacks Research upgraded shares of AC Immune from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 29th. Finally, HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Thursday, September 24th.

View Our Latest Stock Report on ACIU

Institutional Investors Weigh In On AC Immune

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership boosted its holdings in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares during the period. Finally, AXQ Capital LP purchased a new position in AC Immune in the 2nd quarter valued at $25,000. 51.36% of the stock is owned by hedge funds and other institutional investors.

AC Immune Stock Performance

Shares of ACIU stock opened at $2.57 on Thursday. AC Immune has a fifty-two week low of $2.10 and a fifty-two week high of $4.00. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $2.65. The stock has a market capitalization of $261.55 million, a P/E ratio of -4.76 and a beta of 1.56.

AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. On average, research analysts forecast that AC Immune will post -0.6 EPS for the current fiscal year.

About AC Immune

(Get Free Report)

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. The company develops precision medicines and diagnostic products for neurodegenerative diseases, with a primary focus on Alzheimer’s disease and other conditions involving the abnormal accumulation or misfolding of proteins in the brain.

AC Immune’s research platform includes SupraAntigen, which is designed to generate antibodies against pathological forms of proteins, and Morphomer, a technology focused on identifying small molecules that can target and potentially prevent protein misfolding.